Fibromyalgia Treatment Market, by Drug Class (Antidepressants (Milnacipran (Savella and Other Generics), Duloxetine (Cymbalta and Other Generics), and Others), Antiepileptics (Pregabalin (Lyrica and Other Generics), and Others), Muscle Relaxants, Analgesi

Fibromyalgia Treatment Market, by Drug Class (Antidepressants (Milnacipran (Savella and Other Generics), Duloxetine (Cymbalta and Other Generics), and Others), Antiepileptics (Pregabalin (Lyrica and Other Generics), and Others), Muscle Relaxants, Analgesics, and Others (Including Pipeline Drugs)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue, and localized tenderness affecting individuals mentally, physically, and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain, and tender points. An individual with fibromyalgia can also have symptoms such as headaches, muscle pain, burning, twitching, or tightness, poor concentration, draining fatigue and depression. Fibromyalgia symptoms might accumulate with time or it can be caused by some external factors. Fibromyalgia treatments include therapy, medications, regular aerobic exercise, stress reduction, and others. Furthermore, for the treatment of fibromyalgia, antidepressants or pain medications are prescribed to treat depression, anxiety, pain, and fatigue. The FM/a Test is a blood test used for the diagnosis of fibromyalgia. It is available for use in patients of any age who have at least four of the typical symptoms of fibromyalgia. The three drugs approved specifically for fibro pain are Duloxetine (Cymbalta), Milnacipran (Savella), Pregabalin (Lyrica). Over-the-counter painkillers are used in treating fibromyalgia. Stronger medicines, like opioids,are not prescribed for long term use, and you could become dependent on them.

Market Dynamics

Key players in the market are focusing on research and development activities for the development of novel medications for fibromyalgia treatment. Launch of novel drugs in the market for fibromyalgia is expected to boost the fibromyalgia treatment market growth over the forecast period.

For instance, in December 2018, Aptinyx Inc., Biotech Company announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study received daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.

In 2017, Virios Therapeutics, Biotechnology company announced that the Journal of Pain Research published the key topline results from the Phase 2 PRID-201 trial of IMC-1 for the treatment of fibromyalgia. This 16 week, randomized double-blinded, placebo-controlled study was conducted at 12 research centers in the U.S. and enrolled 143 patients with fibromyalgia, as defined by the ACR 2010 criteria. The PRID-201 study demonstrated that patients randomized to IMC-1 (celecoxib+famciclovir) experienced a significant decrease in fibromyalgia-related pain vs patients randomized to placebo.

Moreover, over the past few years, leading generic manufacturers such as Sun Pharmaceutical Industries Ltd., Mylan N.V., and Teva Pharmaceuticals Industries Ltd. launched generic drugs for fibromyalgia treatment in the market.

Furthermore, in September 2021, University of Alabama at Birmingham, carried out a study to evaluate if Dextromethorphan (DXM) reduces Fibromyalgia (FM) pain. Dextromethorphan (DXM) is a drug found in several over-the-counter products, including cough suppressants. The drug may reduce Fibromyalgia (FM) pain by suppressing inflammation in the central nervous system. The Dextromethorphan (DXM) is still in phase 2 trial.

Key features of the study:

• This report provides an in-depth analysis of the global fibromyalgia treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global fibromyalgia treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global fibromyalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibromyalgia treatment market

Detailed Segmentation:

• Global Fibromyalgia Treatment Market, By Drug Class:
• Antidepressants
• Milnacipran (Savella and Other Generics)
• Duloxetine (Cymbalta and Other Generics)
• Others
• Antiepileptics
• Pregabalin (Lyrica and Other Generics)
• Others
• Muscle Relaxants
• Analgesics
• Others (Including Pipeline Drugs)
• Global Fibromyalgia Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Fibromyalgia Treatment Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Eli Lilly and Company*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Pfizer, Inc.
• Novartis AG
• Allergan plc.
• Sun Pharmaceutical Industries Ltd.
• Aptinyx, Inc.
• Prismic Pharmaceuticals, Inc.
• Innovative Med Concepts, Inc.
• Intec Pharma Ltd.
• Astellas Pharma Inc.

“*” marked represents similar segmentation in other categories in the respective section.